QRICH1 Drives ER Stress-Mediated HMGB1 Secretion in HBV Fibrosis

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection remains a leading driver of hepatic fibrosis and eventual cirrhosis, with adverse outcomes rooted in both direct viral effects and the host response. High mobility group box 1 (HMGB1), a nuclear protein, becomes a potent damage-associated molecular pattern (DAMP) when secreted, actively participating in inflammatory signaling and tissue injury. The mechanisms underlying HMGB1 release during HBV-induced hepatic fibrosis, particularly the contribution of endoplasmic reticulum (ER) stress and its downstream effectors, have not been fully elucidated. QRICH1, known for its role in ER stress adaptation, is upregulated in cirrhotic and inflamed liver tissue, but its specific function in HBV-related fibrosis has remained unclear until now.

Key Innovation from the Reference Study

The reference study by Feng et al. (2025) delivers a significant advance by demonstrating that QRICH1 is not only elevated in HBV-induced fibrosis but is also causally linked to increased HMGB1 transcription, cytoplasmic translocation, and secretion during ER stress. This mechanistic insight positions QRICH1 as a key node connecting ER homeostasis disruption to the pro-inflammatory and pro-fibrogenic environment characteristic of chronic HBV infection. Importantly, the study elucidates how HBV modulates SIRT6 expression, driving HMGB1 acetylation and facilitating its export from the nucleus, with QRICH1 acting upstream in this regulatory cascade.

Methods and Experimental Design Insights

The authors employed a combination of in vivo and ex vivo approaches to interrogate these pathways. A chronic recombinant cccDNA (rcccDNA) mouse model was used to recapitulate persistent HBV infection and associated fibrosis. Immunohistochemistry quantified QRICH1 and HMGB1 levels in both mouse and human liver tissues, while Sirius red and Masson’s trichrome staining characterized collagen deposition and fibrosis severity. Serum HMGB1 and markers of liver injury were measured via ELISA, and HMGB1 cytoplasmic translocation was evaluated using Western blotting and qRT-PCR. Clinical samples from patients with chronic hepatitis B and varying fibrosis stages provided translational relevance to the preclinical findings.

Core Findings and Why They Matter

The study’s central findings are:

• ER stress robustly promotes HBV-induced hepatic fibrosis and enhances HMGB1 secretion in vivo.
• QRICH1 expression is markedly increased in both rcccDNA mice and chronic hepatitis B patients with advanced fibrosis, with a positive correlation between QRICH1 and HMGB1 levels.
• HBV infection leads to downregulation of SIRT6, resulting in enhanced acetylation of HMGB1, which is necessary for its translocation from the nucleus to the cytoplasm and eventual secretion.
• QRICH1 specifically augments HBV-induced HMGB1 transcription and export, establishing it as a key effector within the ER stress–fibrosis axis.

These mechanistic insights clarify how persistent ER stress, mediated by QRICH1, acts in concert with HBV to drive the DAMP-mediated inflammatory cascade, accelerating hepatic fibrosis. By delineating the QRICH1–SIRT6–HMGB1 pathway, the study opens new investigative and potentially therapeutic avenues for modulating fibrosis progression in chronic viral hepatitis.

Comparison with Existing Internal Articles

While the reference paper focuses on QRICH1 and ER stress in HBV-induced fibrosis, several internal resources contextualize these findings within broader research workflows:

• The article "Tetracycline in Advanced Ribosomal and ER Stress Research" reviews how tetracycline, as a broad-spectrum polyketide antibiotic, has become instrumental in dissecting ribosomal function and ER stress responses. While not directly targeting QRICH1, tetracycline-based assays are frequently used to perturb protein synthesis and monitor subsequent ER stress outcomes.
• "Tetracycline: Bridging Ribosomal Inhibition and Translational Insight" underlines the utility of tetracycline as a microbiological research antibiotic and a mechanistic probe for ribosomal function, which is crucial given the liver’s prominence as a protein synthesis hub and a site of ER stress adaptation. These studies reinforce the relevance of ribosomal and ER stress pathway tools in translational liver research.
• The workflow-focused guide "Tetracycline: Mechanisms and Benchmarks for Broad-Spectrum Application" details how tetracycline’s inhibition of bacterial protein synthesis via reversible binding to the bacterial 30S ribosomal subunit enables precise experimental modulation of translation-dependent cellular stress responses, underscoring its value in modeling ER stress phenomena.

Collectively, these resources illustrate how compounds like tetracycline serve as both tools and benchmarks in ribosomal and ER stress research, complementing the QRICH1-focused mechanistic discoveries in the reference study.

Limitations and Transferability

Despite its strengths, the study is subject to certain limitations. The rcccDNA mouse model, while closely paralleling human chronic HBV infection, cannot fully recapitulate the complexities of human immune responses and fibrotic remodeling. The direct molecular interactions between QRICH1, SIRT6, and HMGB1, though strongly inferred, may warrant further validation using loss-of-function and gain-of-function approaches in distinct hepatic cell types. Additionally, while the translational data from HBV patients strengthen the clinical implications, whether QRICH1 modulation can be therapeutically targeted without off-target disruption of essential ER stress responses remains to be seen. These factors should be considered when extrapolating findings to other contexts or disease models.

Protocol Parameters

• Mouse model of chronic HBV infection: Use rcccDNA vectors for stable HBV expression; monitor ER stress markers and fibrosis progression over several weeks (see Feng et al., 2025 for detailed timelines).
• Immunohistochemistry: Quantify QRICH1 and HMGB1 expression in formalin-fixed, paraffin-embedded liver sections; include appropriate negative and positive controls.
• Serum HMGB1 measurement: Employ ELISA kits validated for murine and human samples; standardize sample collection and storage to minimize degradation.
• Collagen quantification: Utilize Sirius red and Masson’s trichrome stains for fibrosis assessment; analyze stained sections with digital image analysis for objective scoring.
• HMGB1 cytoplasmic translocation: Isolate nuclear and cytoplasmic fractions for Western blotting; confirm compartmental purity with appropriate marker proteins.
• qRT-PCR: Amplify HMGB1 and QRICH1 transcripts using validated primer sets; normalize to housekeeping genes (e.g., GAPDH, ACTB).

Why this cross-domain matters, maturity, and limitations

The intersection of ER stress research and liver fibrosis studies is highly consequential, as the liver’s central role in protein synthesis renders it particularly susceptible to disruptions in ER function. The reference study’s mechanistic linkage between QRICH1-mediated ER stress and HBV-induced HMGB1 release exemplifies how insights from molecular cell biology can drive translational advances in hepatology. However, cross-domain application of these findings—such as extending QRICH1 targeting strategies to non-viral or non-hepatic fibrosis—requires careful validation, as ER stress pathways are highly context-dependent and may play divergent roles in different tissues or disease states.

Research Support Resources

Researchers aiming to reproduce or extend these workflows can leverage high-purity experimental reagents such as Tetracycline (SKU C6589), a broad-spectrum polyketide antibiotic well-characterized for its inhibition of bacterial protein synthesis and utility as an antibiotic selection marker in molecular biology. As described in the internal guide, tetracycline’s reliable performance and documented solubility characteristics support robust and reproducible experiments in ribosomal function research and can be integrated into ER stress–related studies. When using APExBIO’s Tetracycline, always follow recommended storage at -20°C and prepare fresh solutions to preserve compound integrity and activity.